Press Releases

 
Press Releases
  Date Title and Summary View
Nov 8, 2016
NOVATO, Calif., Nov. 08, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, will present at the following investor conferences: Shalini Sharp, the company's Chief Financial...
Nov 7, 2016
NOVATO, Calif., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today reported its financial results and corporate update for the quarter ended September 30, 2016. "Based on rec...
Oct 31, 2016
NOVATO, Calif., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it will host a conference call on Monday, November 7, 2016 at 5pm ET to discuss third quarter 2016 finan...
Oct 26, 2016
NOVATO, Calif, Oct. 26, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the initiation of the Phase 3 study of KRN23 for the treatment of pediatric patients with X-linked hypophosph...
Sep 27, 2016
NOVATO, Calif., Sept. 27, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer, will present at the Leerink Partner...
Sep 19, 2016
Pediatric study demonstrates substantial reduction in bone disease and improvement in growth Adult study demonstrates increase in serum phosphorus and provides evidence of clinical improvement Company to host conference call today at 11am ET to discuss res...
Sep 18, 2016
NOVATO, Calif., Sept. 18, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced positive interim data from the Phase 2 study of KRN23 for the treatment of tumor-induced osteomalacia (TIO). Interim data...
Sep 16, 2016
NOVATO, Calif., Sept. 16, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it will host a conference call on Monday, September 19 at 11am ET during which Emil D. Kakkis, M.D., Ph.D., Chief Ex...
Sep 1, 2016
NOVATO, Calif., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Shalini Sharp, the company's Chief Financial Officer, will be presenting at the Baird 2016 Global Healthc...
Aug 23, 2016
NOVATO, Calif., Aug. 23, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced upcoming presentations of data highlighting KRN23 for the treatment of X-linked hypophosphatemia (XLH) and tumor-induced ost...
Page: FirstPrevious
3
... NextLast
= add release to Briefcase